No Data
PKU HealthCare Corp. (000788.SZ): Does not produce Medical testing equipment.
On March 14, according to Gelonghui, PKU HealthCare Corp. (000788.SZ) stated on the investor interaction platform that the company does not produce Medical testing equipment. The company is primarily engaged in the R&D, production, and sales of Chemical Drugs formulations, as well as pharmaceutical distribution and other Businesses. Currently, the focus of the company's Medical manufacturing Sector is on core areas such as anti-infection, analgesics, psychiatry, and chronic diseases, primarily with generic drugs.
PKU HealthCare Corp. (000788.SZ): The ownership structure of the controlling Shareholder has been adjusted.
On February 6, Gelonghui reported that PKU HealthCare Corp. (000788.SZ) announced that this adjustment of the Shareholder structure is due to the adjustment of the upper Shareholder structure of the controlling Shareholder of PKU HealthCare Corp. The limited partner of New Advantage International Business Management (Hangzhou) Partnership (Limited Partnership) (referred to as "New Advantage International") has changed from Zhejiang Zhongbei Jiuzhou Group Co., Ltd. (referred to as "Zhongbei Jiuzhou") to Hangzhou Mingman Investment Management Co., Ltd. (referred to as "Hangzhou Mingman"). The executive managing partner of New Advantage International has not changed and remains as Xintong Yanhe Technology (Hainan) Co., Ltd. (referred to as "Xintong Yanhe"). This refers to the controlling Shareholder.
PKU HealthCare Investing 30 Million Yuan to Establish Drug, Food Additive Subsidiary
Peking University Pharmaceuticals: 2024 Annual Results Forecast
The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.
According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.
The 15% Return Delivered to PKU HealthCareLtd's (SZSE:000788) Shareholders Actually Lagged YoY Earnings Growth
PKU HealthCare Corp.,Ltd.'s (SZSE:000788) 28% Share Price Plunge Could Signal Some Risk
